VX-548 for Acute Pain Relief: Study Summary

This presentation reviews a recent NEJM-published study on VX-548, a selective NaV1.8 inhibitor for acute pain relief, particularly in postoperative settings like abdominoplasty and bunionectomy. The approach, tested in two Phase 2 trials, demonstrated significant pain reduction at high doses with manageable side effects such as nausea and dizziness, without sedation risks. Despite promising outcomes, limitations include a non-diverse population sample and lack of real-world multimodal...